To learn about our parent company, Takeda Pharmaceutical Company Limited, please visit http://www.takeda.com/
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021
Takeda’s LIVTENCITYTM (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare Disease
SEE ALL NEWS AND RELEASES >
Copyright 2022 Takeda Pharmaceutical Company Limited. All rights reserved.Certified Top Employer
You are about to leave www.Takeda.com/en-us and be redirected to another Takeda domain.